Caris Life Sciences, Inc. (CAI): Cash & Equivalents
$796.27M
As of 2025-12-31
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $796.27M | n/m | 2026-03-03, Balance as of period end |
| 2024-12-31 | $63.95M | n/a | 2026-03-03, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $796.27M | n/m |
| Guardant Health, Inc. (GH) | 2025-12-31 | $378.20M | -28.0% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $362.58M | +51.7% |
| CareDx, Inc. (CDNA) | 2025-12-31 | $65.43M | -43.0% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $116.73M | -2.5% |
| RadNet, Inc. (RDNT) | 2025-12-31 | $767.22M | +3.7% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $50.19M | -9.0% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $495.98M | +159.0% |
| Fortrea Holdings Inc. (FTRE) | 2025-12-31 | $174.60M | +47.3% |
Compare CAI, GH, VCYT, CDNA side by side · Screen every company in Services-Medical Laboratories ↗